.gif "IP Gear")
(Hope this helps someone or anyone!)
Scientists have labored to dissociate anabolic from androgenic effects with the hope of producing a purely anabolic agent that is free from any androgenic side effects, since 1996 , pharmaceutical science of development of a PURE ANABOLIC could have been made but more importantly , they could approve older well known AAS like MESTERLONE, Metenolone, Masteron Propionate, Parabolan, Blends and Esters, Prosteroid/Designer with all the added : time releasing, bioavailability, increased Potency, nano emulsions , transdermal, Solid particle
Although androgens mediate a broad range of developmental and homeostatic function, all of the androgens induce their response via a single AR despite this diversity. The receptor is a 120-kDa cytosolic protein encoded on the X chromosome, and to date “only one AR cDNA has been identified”!? As there is only one AR, how do AAS mediate these diverse actions? Attempts in the past have failed to isolate a pure anabolic or a pure androgenic receptor (no one has tried for over 20 years!). These data show that the conversion of AAS in various tissues into different metabolites and the relative binding affinity of these metabolites to AR in these tissues are responsible for its diverse actions. However, in a recent animal study, found two different kinds of androgen response elements that could respond differentially to T and DHT. Therefore, it is possible that a selective androgen response element sequence may play a role in differential T vs. DHT AR trans-activation. **Oxandrolone (a synthetic analog of T) to normal young men resulted in a 44% increase in the fractional synthesis of muscle proteins. Furthermore, oxandrolone administration significantly increased mRNA levels of skeletal muscle AR. Similarly, a single injection of 200 mg T enanthate results in increased skeletal muscle protein synthesis and efficient utilization of amino acids.
Therapies that are currently available include AAS, megestrol acetate (Megace; Bristol-Myers Squibb, Princeton, NJ), GH, high calorie supplements, parenteral nutrition, and exercise. Therapy with Megace typically results in an increase in fat mass. GH use is associated with high cost and some untoward side effects. For this reason, other methods of treatment are in demand !
Studies examining AAS effects on maximal inspiratory pressure (Pmax) have yielded conflicting results.
1-The efficacy of AAS therapy for weight gain in cancer patients has not yet been examined in a clinical trial.
2-AAS therapy has been shown to have positive effects on remission rates in leukemia patients.
3-In addition to increasing lean body mass in dialysis patients
4-AAS also improves erythropoietin synthesis.
5-Oxandrolone treatment in alcoholic hepatitis has yielded significant improvement in liver function.
6-AAS has beneficial effects in preliminary studies.
Real Life Results for People with Serious Diseases !! (READ CLOSELY AS IT MAY HELP SOMEONE YOU KNOW )
In a 4-month randomized, placebo-controlled study of oxandrolone (15 mg/d)in 63 AIDS patients with more than 10% body weight loss, oxandrolone resulted in significant weight gain, increase in appetite, and improvement in physical activity.
•In another study therapy at a dose of 100 mg/wk and randomized to oxandrolone (20 mg/d) or placebo. The patients in the oxandrolone group experienced increase in nitrogen retention, LBM, and muscle strength. Similarly, the use of nandrolone decanoate in this patient population also resulted in a significant increase in weight and LBM.
•Oxymetholone is another oral preparation that has been used to treat HIV wasting with positive effects on total body weight. At a dose of 50 mg three times a day, oxymethalone resulted in an increase of 8.2 kg over a 30-wk period, whereas the subjects on placebo lost 1.8 kg. There was also a significant improvement in the quality of life variables in subjects taking oxymethalone. Damn , 150mg a day for 30 weeks….and they improved significantly in overall “Quality of Life” ! Most important
•Recent studies indicate a potential use for AAS therapy in COPD-associated wasting. A regimen of exercise, 250 mg im Test E administration at the baseline visit, and then 12 mg/d oral stanozolol(Winstrol)for 27 wk showed significant improvement in weight, body mass index, LBM, and muscle size compared with exercise alone in patients with COPD. studied 217 patients with COPD and randomized them to either nandrolone decanoate plus nutrition and exercise or nutrition and exercise alone for a period of 8 wk. There was a significant increase in fat-free mass and an improvement in maximum inspiratory pressure in the *nandrolone group. Similarly, *oxandrolone therapy (20 mg/d) in tetraplegic patients produced significant improvement in weight and respiratory parameters.
End Stage Renal Disease
As parenteral nutrition has proven to be ineffective in improving the nutritional status of these patients, AAS therapy appears to be an exciting alternative. In a recent double blind, placebo-controlled trial, 29 patients were randomized to either placebo or nandrolone decanoate (100 mg/wk, im) for 6 months. Serum creatinine and LBM were significantly greater in the nandrolone group. The results of functional tests such as timed walking and stair-climbing also significantly improved in the nandrolone group, whereas they worsened in the placebo group. In addition to the increase in LBM, patients with chronic renal failure benefit from the stimulation of erythropoiesis resulting from the administration of AAS. A recent study of 25 male anemic patients with normal serum iron levels showed an increase in erythropoietin synthesis in 15 patients treated with nandrolone decanoate (200 mg/wk, im) for 6 months. Although erythropoietin levels returned to baseline 6 wk after the final dose of nandrolone, the hemoglobin concentration remained in the normal range up until 16 wk after discontinuation of nandrolone. Clinical trials have shown that nandrolone decanoate therapy in combination with recombinant human erythropoietin result in a greater increase in hematocrit compared with erythropoietin alone. Based on these positive data, the role of AAS should be further studied in patients with renal failure, especially evaluation of functional status and quality of life.
Liver disease
AAS also have a role in treating patients with hepatitis-related malnutrition. In a study of 271 patients with alcoholic hepatitis, oxandrolone along with a high calorie supplement was compared with placebo and a low calorie supplement. Significant improvement in liver function and overall survival was observed in the oxandrolone and high calorie supplement group. Similarly, oxandrolone therapy has been shown to result in a reduction in 6-month mortality in patients with alcoholic hepatitis! In a V.A. cooperative study of 273 patients with moderate protein calorie malnutrition secondary to alcoholic hepatitis,
80 mg/d oxandrolone along with an enteral food supplement resulted in improved 6-month survival, decrease in liver injury, and improvement in malnutrition compared with the placebo group. “Although this dose of oxandrolone was very high, especially in a population with established liver disease, no hepatotoxicity was reported in subjects taking oxandrolone”. Just last year positive effects of AAS on muscle strength lead to early mobilization and, hence, alleviates the postoperative debilitation associated with knee replacement surgery. In their placebo-controlled trial of T enanthate (600 mg weekly for 3 wk before surgery), there was a significantly shorter in-patient stay and a higher degree of functional independence in patients receiving 600mg T weekly . We know that burn victims improve immensely from GH and Oxandrolone. AAS have a role to play in the treatment of cancer cachexia. However, only a few controlled trials have been performed to ascertain whether this represents an influence of hormones on nutritional intake or vice versa. Preclinical trials with nandrolone decanoate in rats 1988 did not support this hypothesis…..THATS THE F***ing Problem! They don’t do true , up to date studies because they approved 144 new cancer drugs investing billion and billions worldwide, yet they did one study in 1988 on a Rat !?? Shows you that Medicine Not Only Needs to Change, but with knowledge like this being posted and Social Media, Enterprising Young entrepreneurs, doctors, scientist, AI database collaboration…Medicine Is GONNA CHANGE !
Max
Scientists have labored to dissociate anabolic from androgenic effects with the hope of producing a purely anabolic agent that is free from any androgenic side effects, since 1996 , pharmaceutical science of development of a PURE ANABOLIC could have been made but more importantly , they could approve older well known AAS like MESTERLONE, Metenolone, Masteron Propionate, Parabolan, Blends and Esters, Prosteroid/Designer with all the added : time releasing, bioavailability, increased Potency, nano emulsions , transdermal, Solid particle
Although androgens mediate a broad range of developmental and homeostatic function, all of the androgens induce their response via a single AR despite this diversity. The receptor is a 120-kDa cytosolic protein encoded on the X chromosome, and to date “only one AR cDNA has been identified”!? As there is only one AR, how do AAS mediate these diverse actions? Attempts in the past have failed to isolate a pure anabolic or a pure androgenic receptor (no one has tried for over 20 years!). These data show that the conversion of AAS in various tissues into different metabolites and the relative binding affinity of these metabolites to AR in these tissues are responsible for its diverse actions. However, in a recent animal study, found two different kinds of androgen response elements that could respond differentially to T and DHT. Therefore, it is possible that a selective androgen response element sequence may play a role in differential T vs. DHT AR trans-activation. **Oxandrolone (a synthetic analog of T) to normal young men resulted in a 44% increase in the fractional synthesis of muscle proteins. Furthermore, oxandrolone administration significantly increased mRNA levels of skeletal muscle AR. Similarly, a single injection of 200 mg T enanthate results in increased skeletal muscle protein synthesis and efficient utilization of amino acids.
Therapies that are currently available include AAS, megestrol acetate (Megace; Bristol-Myers Squibb, Princeton, NJ), GH, high calorie supplements, parenteral nutrition, and exercise. Therapy with Megace typically results in an increase in fat mass. GH use is associated with high cost and some untoward side effects. For this reason, other methods of treatment are in demand !
Studies examining AAS effects on maximal inspiratory pressure (Pmax) have yielded conflicting results.
1-The efficacy of AAS therapy for weight gain in cancer patients has not yet been examined in a clinical trial.
2-AAS therapy has been shown to have positive effects on remission rates in leukemia patients.
3-In addition to increasing lean body mass in dialysis patients
4-AAS also improves erythropoietin synthesis.
5-Oxandrolone treatment in alcoholic hepatitis has yielded significant improvement in liver function.
6-AAS has beneficial effects in preliminary studies.
Real Life Results for People with Serious Diseases !! (READ CLOSELY AS IT MAY HELP SOMEONE YOU KNOW )
In a 4-month randomized, placebo-controlled study of oxandrolone (15 mg/d)in 63 AIDS patients with more than 10% body weight loss, oxandrolone resulted in significant weight gain, increase in appetite, and improvement in physical activity.
•In another study therapy at a dose of 100 mg/wk and randomized to oxandrolone (20 mg/d) or placebo. The patients in the oxandrolone group experienced increase in nitrogen retention, LBM, and muscle strength. Similarly, the use of nandrolone decanoate in this patient population also resulted in a significant increase in weight and LBM.
•Oxymetholone is another oral preparation that has been used to treat HIV wasting with positive effects on total body weight. At a dose of 50 mg three times a day, oxymethalone resulted in an increase of 8.2 kg over a 30-wk period, whereas the subjects on placebo lost 1.8 kg. There was also a significant improvement in the quality of life variables in subjects taking oxymethalone. Damn , 150mg a day for 30 weeks….and they improved significantly in overall “Quality of Life” ! Most important
•Recent studies indicate a potential use for AAS therapy in COPD-associated wasting. A regimen of exercise, 250 mg im Test E administration at the baseline visit, and then 12 mg/d oral stanozolol(Winstrol)for 27 wk showed significant improvement in weight, body mass index, LBM, and muscle size compared with exercise alone in patients with COPD. studied 217 patients with COPD and randomized them to either nandrolone decanoate plus nutrition and exercise or nutrition and exercise alone for a period of 8 wk. There was a significant increase in fat-free mass and an improvement in maximum inspiratory pressure in the *nandrolone group. Similarly, *oxandrolone therapy (20 mg/d) in tetraplegic patients produced significant improvement in weight and respiratory parameters.
End Stage Renal Disease
As parenteral nutrition has proven to be ineffective in improving the nutritional status of these patients, AAS therapy appears to be an exciting alternative. In a recent double blind, placebo-controlled trial, 29 patients were randomized to either placebo or nandrolone decanoate (100 mg/wk, im) for 6 months. Serum creatinine and LBM were significantly greater in the nandrolone group. The results of functional tests such as timed walking and stair-climbing also significantly improved in the nandrolone group, whereas they worsened in the placebo group. In addition to the increase in LBM, patients with chronic renal failure benefit from the stimulation of erythropoiesis resulting from the administration of AAS. A recent study of 25 male anemic patients with normal serum iron levels showed an increase in erythropoietin synthesis in 15 patients treated with nandrolone decanoate (200 mg/wk, im) for 6 months. Although erythropoietin levels returned to baseline 6 wk after the final dose of nandrolone, the hemoglobin concentration remained in the normal range up until 16 wk after discontinuation of nandrolone. Clinical trials have shown that nandrolone decanoate therapy in combination with recombinant human erythropoietin result in a greater increase in hematocrit compared with erythropoietin alone. Based on these positive data, the role of AAS should be further studied in patients with renal failure, especially evaluation of functional status and quality of life.
Liver disease
AAS also have a role in treating patients with hepatitis-related malnutrition. In a study of 271 patients with alcoholic hepatitis, oxandrolone along with a high calorie supplement was compared with placebo and a low calorie supplement. Significant improvement in liver function and overall survival was observed in the oxandrolone and high calorie supplement group. Similarly, oxandrolone therapy has been shown to result in a reduction in 6-month mortality in patients with alcoholic hepatitis! In a V.A. cooperative study of 273 patients with moderate protein calorie malnutrition secondary to alcoholic hepatitis,
80 mg/d oxandrolone along with an enteral food supplement resulted in improved 6-month survival, decrease in liver injury, and improvement in malnutrition compared with the placebo group. “Although this dose of oxandrolone was very high, especially in a population with established liver disease, no hepatotoxicity was reported in subjects taking oxandrolone”. Just last year positive effects of AAS on muscle strength lead to early mobilization and, hence, alleviates the postoperative debilitation associated with knee replacement surgery. In their placebo-controlled trial of T enanthate (600 mg weekly for 3 wk before surgery), there was a significantly shorter in-patient stay and a higher degree of functional independence in patients receiving 600mg T weekly . We know that burn victims improve immensely from GH and Oxandrolone. AAS have a role to play in the treatment of cancer cachexia. However, only a few controlled trials have been performed to ascertain whether this represents an influence of hormones on nutritional intake or vice versa. Preclinical trials with nandrolone decanoate in rats 1988 did not support this hypothesis…..THATS THE F***ing Problem! They don’t do true , up to date studies because they approved 144 new cancer drugs investing billion and billions worldwide, yet they did one study in 1988 on a Rat !?? Shows you that Medicine Not Only Needs to Change, but with knowledge like this being posted and Social Media, Enterprising Young entrepreneurs, doctors, scientist, AI database collaboration…Medicine Is GONNA CHANGE ! Max
